Mel, on the Yahoo Message board wrote this 2 hours
Post# of 148187
Ocoimmune's drug, like Remdesivir, is an IV administered drug. It shows promise but is very complex to make, so ramping up production will be a major challenge. Unlikely to have any doses ready until mid-2021. They stated they won't be making an EUA request until they can produce. At 50% clinically improved, it's promising but still less promising than Leronlimab and Aviptadil in my opinion.